Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Charles River Laboratories International, Inc. (CRL) — XLV Health Care · S&P 500 Profile |Charles River公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Charles River Laboratories International, Inc. (CRL) — Business, History & S&P 500 Profile | Charles River公司介紹

Charles River Laboratories International, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #430 · Charles River公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 4, 2026
Financials: FY2025
MARKET CAP
$16.80B
Nov 4, 2026
S&P 500 WEIGHT
0.02%
Rank #430 · Nov 4, 2026
SECTOR RANK
#51
Health Care · Nov 4, 2026
S&P 500 RANK
#430
0.02% · Nov 4, 2026

SNAPSHOT

TickerCRL
CompanyCharles River Laboratories International, Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#430 · 0.02% (Nov 4, 2026)
Sector rank#51 of 60 in Health Care (Nov 4, 2026)
HeadquartersWilmington, Massachusetts
Founded1947
CEOBirgit Girshick (President and CEO since May 5, 2026; succeeded James C. Foster, CEO throughout FY2025)
Employees19,700 (as reported; 10-K as-of year to confirm)
Market cap$16.80B (Nov 4, 2026)
SEC filingsEDGAR — CIK 0001100682

WHAT IT DOES

Charles River Laboratories International, Inc. is a contract research organisation providing research models, discovery and safety-assessment services, and manufacturing testing that help pharmaceutical and biotechnology companies develop new medicines, headquartered in Wilmington, Massachusetts. Its laboratories test drugs for safety and efficacy before human trials.

Its one-line model: sell preclinical science as a service — bred research animals, safety studies and quality testing — to drug developers that outsource early development. Fiscal 2025 total revenue was $4.02B, but GAAP operating income collapsed to $25.2M and the company recorded a net loss available to common shareholders of $144.3M after large fourth-quarter charges including a $165.0M goodwill impairment.

The moat is validation and trust: safety data must satisfy regulators, and switching providers mid-programme is costly. Growth depends on biotech funding recovery, discovery demand and the reshaped portfolio after the February 2026 CDMO and discovery-services divestitures.

BUSINESS SEGMENTS

Research Models and Services (RMS)Purpose-bred rodents (rats and mice) and related research models and services. Fiscal 2025 revenue $846.1M (2024: $829.4M, +2.0%).
Discovery and Safety Assessment (DSA)Early discovery, in vivo discovery, safety assessment and toxicology, pathology and bioanalysis. The largest segment, about 60% of revenue. Fiscal 2025 revenue $2.40B (2024: $2.45B, down 2.0%; down 2.6% organic).
Manufacturing Solutions (Manufacturing)In vitro microbial and quality-control testing for sterile and non-sterile pharmaceuticals and consumer products, plus contract development and manufacturing (CDMO, divested February 2026). Fiscal 2025 revenue $766.4M.
Rounded segment figures sum to $4,012.5M versus the $4,015.4M total — an approximately $2.9M rounding gap; verify exact thousands in the 10-K segment note at posting.

HISTORY

YearMilestone
1947Dr. Henry Foster founds Charles River Breeding Laboratories in a second-floor Boston loft overlooking the Charles River, breeding Sprague-Dawley rats.
1952Relocates to 60 acres of farmland in Wilmington, Massachusetts (eventual headquarters campus).
1968First IPO on NASDAQ (offering size differs by source and is omitted here).
1984Acquired by Bausch & Lomb.
1999Management-led leveraged buyout from Bausch & Lomb; the holding company is renamed Charles River Laboratories International.
2000Second IPO on the NYSE (CRL); raised $224M per encyclopaedia summary.

COMPETITIVE POSITION

  • Purpose-bred models: a long-established, quality-controlled supply of research rats and mice that drug developers trust.
  • Integrated preclinical breadth: research models, discovery and safety assessment, and manufacturing testing under one roof.
  • Regulatory moat: safety-assessment studies must meet strict standards, and switching a validated provider mid-programme is costly.
  • Competition set (contract research and preclinical): IQVIA, Labcorp Drug Development (Covance), ICON plc, WuXi AppTec, Medpace and Thermo Fisher Scientific (PPD).

FINANCIAL SNAPSHOT

Total revenue$4.02B (FY2025 revenue)
Operating income$25.2M (FY2025 operating income)
Net income$(144.3)M (FY2025 net income)
Diluted EPS$(2.91) (FY2025 diluted EPS)
Source: Charles River Laboratories International, Inc. fiscal 2025 Form 10-K (year ended December 27, 2025; filed February 18, 2026) and Q4/full-year 2025 results release. Exact figures: total revenue $4,015.4M (2024: $4,050.0M; down 0.9% reported, down 1.6% organic); GAAP operating income $25.162M (2024: $227.347M), GAAP operating margin 0.6% (2024: 5.6%); net loss available to common shareholders $(144.3)M (2024: net income $10.3M); diluted EPS (GAAP) $(2.91) (2024: $0.20). The operating collapse reflects large fourth-quarter 2025 GAAP charges (Q4 GAAP operating loss $(283.440)M; Q4 GAAP operating margin minus 28.5%), including a $165.0M goodwill impairment. A TradingKey operating income of $502.15M is inconsistent with the GAAP schedule and likely non-GAAP or mislabelled; it was not used. Some tables show net income from continuing operations $(142.2)M versus GAAP net $(144.3)M; the available-to-common figure is the headline here. Non-GAAP context: non-GAAP net income $512.3M; non-GAAP diluted EPS $10.28 (2024: $10.32). Employee figure 19,700 is a MarketBeat and CSIMarket profile figure; the year was not precisely tied to the 10-K in the sources retrieved and should be confirmed against the fiscal 2025 10-K Human Capital section at posting. Post-period: in February 2026 the CDMO business was sold to GI Partners (formed as Rose BioSolutions) and discovery services were sold to IQVIA for $145M.

KEY RISKS

  • Biotech funding cycles: client research budgets drive demand; funding downturns cut preclinical outsourcing quickly.
  • Goodwill and asset risk: the fiscal 2025 impairments show acquired values can fall when growth expectations reset.
  • Animal-welfare and regulatory scrutiny: research-model work faces ethical, regulatory and reputational pressure.
  • Competition from larger CROs: IQVIA, Labcorp and Thermo Fisher compete across discovery, safety and manufacturing.

WHY IT MATTERS FOR THE S&P 500

Charles River is a small-weight health care constituent: rank #430 by weight at 0.02% as of Nov 4, 2026, and #51 in Health Care. As the leading independent preclinical research provider, it is a direct read on drug-development spending — the outsourced safety and discovery work behind new medicines.

SOURCES & METHODOLOGY

Financials, segments, headquartersCharles River Laboratories International, Inc. fiscal 2025 Form 10-K via SEC EDGAR and Q4/full-year 2025 results release (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$16.80B (Slickcharts, Nov 4, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

CRL

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號CRL
公司Charles River Laboratories International, Inc.(Charles River)
GICS 板塊/行業健康護理(XLV)/生命科學工具及服務
標普500排名(按權重)#430 · 0.02%(Nov 4, 2026)
板塊內排名健康護理板塊 #51(共 60 家)(Nov 4, 2026)
總部美國麻薩諸塞州威爾明頓
成立1947年
執行長Birgit Girshick(總裁兼執行長,自2026年5月5日起接任;James C. Foster 為2025財年執行長)
員工19,700人(據報道;10-K 截至年份待確認)
市值$16.80B(Nov 4, 2026)
SEC 申報EDGAR — CIK 0001100682

業務概覽

Charles River Laboratories International, Inc. 是合約研究機構,提供研究模型、發現與安全評估服務及製造測試,協助製藥與生物科技公司開發新藥,總部位於麻薩諸塞州威爾明頓。實驗室在人體試驗前測試藥物的安全性與療效。

其一句話商業模式是:以服務形式銷售臨床前科學——繁殖研究動物、安全研究與質量測試——予外包早期開發的藥物開發商。2025 財年總收入 40.15 億美元,但 GAAP 營業利潤急跌至 0.25 億美元,歸屬普通股股東淨虧損 1.44 億美元,原因是第四季龐大費用,包括 1.65 億美元商譽減值。

護城河是驗證與信任:安全數據須令監管機構滿意,計劃中途轉換供應商成本高昂。增長依賴生物科技資金復甦、發現需求,以及 2026 年 2 月 CDMO 與發現服務剝離後的重塑組合。

業務板塊

研究模型及服務專用繁殖齧齒動物(大鼠與小鼠)及相關研究模型與服務。2025 財年收入 8.461 億美元(2024 年:8.294 億美元,增長 2.0%)。
發現及安全評估早期發現、體內發現、安全評估與毒理學、病理學及生物分析。最大板塊,約佔收入 60%。2025 財年收入 24.0 億美元(2024 年:24.5 億美元,下跌 2.0%;有機下跌 2.6%)。
製造方案無菌與非無菌藥品及消費品的體外微生物與質量控制檢測,以及合約開發與製造(CDMO,2026 年 2 月剝離)。2025 財年收入 7.664 億美元。
約數板塊數字合計 40.125 億美元,對比總數 40.154 億美元——約 0.029 億美元四捨五入差額;發佈時應按 10-K 板塊附註核實準確千位數字。

歷史

年份里程碑
1947Henry Foster 博士在俯瞰查爾斯河的波士頓二樓閣樓創立 Charles River Breeding Laboratories,繁殖 Sprague-Dawley 大鼠。
1952遷往麻薩諸塞州威爾明頓 60 英畝農地(日後總部園區)。
1968首次在納斯達克公開招股(發行規模因來源而異,此處從略)。
1984由 Bausch & Lomb 收購。
1999管理層主導槓桿收購,自 Bausch & Lomb 回購;控股公司更名為 Charles River Laboratories International。
2000第二次在紐約證券交易所公開招股(CRL);按百科摘要集資 2.24 億美元。

競爭地位

  • 專用繁殖模型:長期建立、質量受控的研究大鼠與小鼠供應,深受藥物開發商信任。
  • 綜合臨床前廣度:研究模型、發現與安全評估、製造測試集於一身。
  • 監管護城河:安全評估研究須符合嚴格標準,計劃中途轉換已驗證供應商成本高昂。
  • 競爭對手(合約研究與臨床前):IQVIA、Labcorp Drug Development(Covance)、ICON plc、WuXi AppTec、Medpace 與 Thermo Fisher Scientific(PPD)。

財務快照

總收入40.15 億美元(2025 財年收入)
營業利潤0.25 億美元(2025 財年營業利潤)
淨利潤虧損1.44億美元(2025 財年淨利潤)
稀釋 EPS虧損2.91美元(2025 財年稀釋 EPS)
來源:Charles River Laboratories International, Inc. 2025 財年 Form 10-K(截至 2025 年 12 月 27 日;2026 年 2 月 18 日申報)及 2025 年第四季/全年業績公佈。精確數字:總收入 40.154 億美元(2024 年:40.50 億美元;申報下跌 0.9%,有機下跌 1.6%);GAAP 營業利潤 0.25162 億美元(2024 年:2.27347 億美元),GAAP 營業利潤率 0.6%(2024 年:5.6%);歸屬普通股股東淨虧損 (1.443) 億美元(2024 年:淨利潤 0.103 億美元);稀釋 EPS(GAAP)(2.91) 美元(2024 年:0.20 美元)。營業利潤急跌反映 2025 年第四季龐大的 GAAP 費用(第四季 GAAP 營業虧損 (2.8344) 億美元;第四季 GAAP 營業利潤率負 28.5%),包括 1.65 億美元商譽減值。TradingKey 的 5.0215 億美元營業利潤與 GAAP 報表不符,可能為非 GAAP 或標示錯誤,未予採用。部分表格顯示持續經營淨利潤 (1.422) 億美元,對比 GAAP 淨額 (1.443) 億美元;此處以歸屬普通股數字為標題。非 GAAP 背景:非 GAAP 淨利潤 5.123 億美元;非 GAAP 稀釋 EPS 10.28 美元(2024 年:10.32 美元)。員工人數 19,700 人為 MarketBeat 與 CSIMarket 資料數字;年份未在來源中準確對應 10-K,發佈前應按 2025 財年 10-K 人力資本章節確認。期後事項:2026 年 2 月 CDMO 業務售予 GI Partners(組成 Rose BioSolutions),發現服務以 1.45 億美元售予 IQVIA。

主要風險

  • 生物科技資金週期:客戶研究預算驅動需求;資金下行會迅速削減臨床前外包。
  • 商譽與資產風險:2025 財年減值顯示增長預期重設時,收購價值可下跌。
  • 動物福利與監管審查:研究模型工作面臨道德、監管與聲譽壓力。
  • 大型合約研究機構競爭:IQVIA、Labcorp 與 Thermo Fisher 在發現、安全與製造領域競爭。

對標普500的重要性

Charles River 是權重較小的健康護理成分股:按權重排名 #430,權重 0.02%(以 2026 年 11 月 4 日為準),健康護理板塊內排名 #51。作為領先的獨立臨床前研究供應商,它是藥物開發開支的直接指標——新藥背後外包的安全與發現工作。

來源與方法

財務、板塊、總部Charles River Laboratories International, Inc. 2025 財年 Form 10-K 數據,經 SEC EDGAR 及 2025 年第四季/全年業績公佈(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司資料
指數權重與排名Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$16.80B(Slickcharts,Nov 4, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

CRL

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · CRL
Data as of Nov 4, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Erie Indemnity Company (ERIE) — XLF Financials · S&P 500 Profile |伊利介紹Next · Leidos Holdings, Inc. (LDOS) — XLI Industrials · S&P 500 Profile |Leidos公司介紹

Entered 2026-11-04 02:38 · updated 2026-11-14 23:14 · rev 6